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Evolving importance of kidney disease: fro m subspecialty to 
global health burden 
 
Kai-Uwe Eckardt, Josef Coresh, Olivier Devuyst, Richard J Johnson, Anna Köttgen, Andrew S Levey, Adeera Levin 
 
In the past decade, kidney disease  diagnosed  with objective measures  of kidney damage  and  function has  been 
recognised as a major public health burden. The population prevalence of chronic kidney disease exceeds 10%, and is 
more than 50% in high-risk subpopulations. Independent of age, sex, ethnic group, and comorbidity, strong, graded, 
and consistent associations exist between clinical prognosis and two hallmarks of chronic kidney disease: reduced 
glomerular ﬁltration rate and increased urinary albumin excretion. Furthermore, an acute reduction in glomerular 
ﬁltration rate is a risk factor for adverse clinical outcomes and the development and progression of chronic kidney 
disease. An increasing amount of evidence suggests that the kidneys are not only target organs of many diseases but 
also can strikingly aggravate or start systemic  pathophysiological processes  through their complex functions and 
eﬀects on body homoeostasis. Risk of kidney disease  has a notable genetic component, and identiﬁed genes  have 
provided new insights into relevant abnormalities in renal structure and function and essential homoeostatic 
processes.  Collaboration across  general  and  specialised  health-care professionals  is  needed  to fully  address  the 
challenge of prevention of acute and chronic kidney disease and improve outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
More  than   50   years   ago,  nephrology  emerged   as   a 
medical subspecialty dealing with the eﬀects of severely 
impaired kidney function on body homoeostasis. At that 
time, the understanding of renal physiology and the 
complex and diverse involvement of kidney function on 
various body functions was ahead of its clinical appli- 
cation. Few options to treat renal  disorders  of mineral 
and electrolyte handling existed, hormonal deﬁciencies 
resulting from kidney disease could not be corrected, and 
almost no techniques were available to prolong the life of 
individuals with kidney failure. 
Nephrology progressed gradually with the establish- 
ment  of renal pathology and a better understanding  of 
disease   entities,  but  the  ﬁrst  major  change  occurred 
when  dialysis and transplantation became  widely avail- 
able in the 1960s. The ability to provide life-sustaining 
renal replacement therapy was an outstanding achieve- 
ment in medicine. Unsurprisingly, nephrologists have 
since strived to optimise renal replacement therapy and 
 
 
which creates striking social inequalities and pressure on 
constrained health-care resources.3 
By contrast with the importance and obvious relevance 
of chronic kidney failure requiring replacement therapy, 
the eﬀect of less severe chronic kidney disease, which 
aﬀects far more patients, had for a long time been largely 
ignored by the medical community, policy makers,  and 
the public. Reduced kidney function was thought to be of 
little importance until the glomerular ﬁltration rate 
reached  less  than 15%. This viewpoint resulted  in  two 
sets of terms to distinguish between patients with so- 
called end-stage renal  disease  and  others  with a  lesser 
degree of renal impairment, who were often collectively 
summarised   as  pre-end-stage renal  disease  or  pre- 
dialysis patients. Moreover, numerous  vague and poorly 
deﬁned terms were commonly used (eg, renal insuf- 
ﬁciency  or  pre-uraemia)  in  parallel  to  nomenclature 
 
 
 
the prevention and treatment of comorbidities in patients 
with renal failure. However, the costs associated with 
these achievements are high. In countries that can aﬀord 
to oﬀer renal replacement therapy to all patients with 
renal failure, the proportion of health-care expenditure 
for this group of patients is far out of proportion to its 
size.1,2 In most countries, economic constrains allow only 
restricted  access  to  this  expensive  chronic  treatment, 
 
 
  
 
 
 
 
 
describing the cause of kidney disease (eg, glomerulo- 
nephritis, polycystic kidney disease, or diabetic nephrop- 
athy). However a uniform and unequivocal deﬁnition of 
chronic kidney disease was unavailable. 
Only in 2002 did the medical community ﬁrst agree on 
a uniform deﬁnition and staging system for chronic 
kidney disease,  based  on  measures  of kidney function 
and independent of the cause of impaired kidney 
function.4,5  Application of this uniform  concept to large 
databases showed that chronic kidney disease is far more 
frequent  than  was  appreciated  previously.6    More  than 
10% of people have chronic kidney disease and the overall 
prevalence at least equals that of diabetes.7 As with many 
other chronic diseases, the prevalence of chronic kidney 
disease increases with age, exceeding 20% in individuals 
older than 60 years and 35% in those older than 70 years.8 
The importance of chronic kidney disease became 
apparent when large analyses showed that even early- 
stage disease is associated with increased prevalence and 
severity of numerous disorders and adverse outcomes. In 
particular, chronic kidney disease is now recognised as a 
very relevant and independent cardiovascular risk factor 
(see paper 5 in this Series).9,10 
Similar considerations hold true for acute changes in 
kidney function. Acute renal failure was well known to be 
associated with poor prognosis, but was regarded as 
harmless and reversible for a long time, provided patients 
survived the critical condition during which it occurred. 
However, even small, transient changes in serum creatin- 
ine (suggesting temporary decreases in glomerular ﬁl- 
tration rate) have been associated with signiﬁcantly 
worsened prognosis, including a strikingly increased risk 
of mortality and development and progression of chronic 
kidney disease.11,12  After several initiatives were under- 
taken, a uniform  deﬁnition and staging of what is now 
known as acute kidney injury was developed, which could 
potentially further advance the specialty.13 
These developments, which were not based on technical, 
surgical, or immunological progress, but rather on a 
consensus for a uniform terminology and its application 
with rigorous epidemiological methods, has greatly ex- 
panded the focus on kidney disease beyond nephrology. 
Standardised terminology has stimulated research, aﬀected 
patient care, and inﬂuenced public policies. And, as for any 
major advancement, it has also raised new questions. The 
seemingly   most  straightforward,  but  most  pressing,  of 
these questions are why is kidney disease so frequent and 
why is it associated with such a poor prognosis? To answer 
these two questions, researchers  might need to return to 
the physiology of the organ to better understand why the 
kidney is a frequent target of many  chronic disturbances 
and why, conversely, disorders of kidney function aﬀect 
extrarenal tissues so strikingly, in particular the cardio- 
vascular system. Aspects of renal function generally 
accepted to be understood need to be revisited. Additionally, 
linkage   of   the   new   deﬁnitions   and   staging   of   acute 
and chronic kidney disease with genomic, proteomic, and 
metabolomic information oﬀers new opportunities to 
understand underlying mechanisms of disease. 
Here, we aim  to review the central role of the kidney 
for body homoeostasis  and its fate as  a target organ of 
disease. We will also describe the current deﬁnitions and 
staging systems for chronic kidney disease and acute 
kidney injury, and advances in understanding of the 
genetic predisposition to kidney disease. Subsequent 
articles in this series will focus on the global eﬀects, 
clinical consequences,  and  management  of chronic 
kidney disease14   and acute kidney injury;15   the link 
between kidney disease and cardiovascular disease;16  the 
eﬀects of maternal, neonatal, and child health on kidney 
health;17   and future perspectives of the specialty.18 
The kidney and body function 
Each kidney contains about 1  million functional units, 
nephrons,    consisting    of   numerous    specialised    cell 
types originating from distinct embryological lineages 
(ﬁgure   1).  Each  nephron   contains   a   ﬁltrating  body, 
the    glomerulus,    and    a    long    tubule    made    of    a 
dozen diﬀerentiated segments.  The ﬁnal parts of these 
tubules are interconnected to form the collecting ducts, 
which open into the renal pelvis. 
The basic  principles  of kidney physiology dictate the 
central role played by this organ in excretory, metabolic, 
and endocrine functions. Although the kidneys excrete 
only about 1·5  L  of urine  daily, they are  perfused  with 
20% of the cardiac output and form about 180 L of 
ultraﬁltrate every day, which is profoundly modiﬁed 
during tubular passage. This function exposes the kidney 
to the interior milieu unlike any other organ and at the 
same time makes the body composition very sensitive to 
changes in kidney function. 
The glomerular ﬁltration barrier consists of the fenes- 
trated endothelial cells, an elaborate basement mem- 
brane, and an intricate layer formed by the foot processes 
of highly diﬀerentiated epithelial cells called podocytes.19 
The ﬁltration barrier is permeable to water, small solutes, 
and  low-molecular-weight proteins  up  to  the  mass   of 
albumin,  but largely precludes  the ﬁltration of plasma 
proteins with a mass of more than 60--70 kDa, especially 
if they are negatively charged. Thus the glomerular 
ﬁltration rate, the product of the ﬁltration area, the 
hydraulic  permeability, and  the net ultraﬁltration pres- 
sure, yields a large ultraﬁltrate containing plasma solutes 
and several grams of low-molecular-weight proteins. Any 
disturbance in glomerular haemodynamics or structure 
can result in reduced glomerular ﬁltration rate or 
increased leakage of proteins into the urine----two classic 
signs of renal disease. 
Along the tubular segments of the nephron, the 
ultraﬁltrate undergoes a series  of modiﬁcations with 
massive  reabsorption of low-molecular-weight proteins, 
solutes, and water, secretion of a gel-like protein called 
uromodulin (Tamm-Horsfall protein) and elimination of 
excess potassium, acids, and bases (ﬁgure 1).20 
  
 
 
The processes   aﬀecting  urine  composition  are 
mediated by polarised transport systems operating in the 
epithelial cells lining the tubules. The proximal  tubule 
reabsorbs  the bulk (about two-thirds) of ﬁltered solutes 
and water. In addition the cells lining these tubules 
possess  multiligand receptors involved in the endocytic 
uptake of ﬁltered proteins that include hormones, carrier 
proteins (eg, for vitamins), and enzymes. Once re- 
absorbed, these proteins are metabolised by proximal 
tubular cells, as  the human  urine  is virtually devoid of 
plasma proteins under physiological conditions. This 
massive uptake of proteins plays an important role in 
metabolic clearance, hormone homoeostasis, and con- 
servation  of  essential  vitamins  (vitamin  D, vitamin  A, 
and vitamin B12), and provides a protein-free milieu for 
the cells lining distal nephron segments.21  Organic 
molecules  and  drug  metabolites  are  secreted  into  the 
urine via speciﬁc transporters located in the last part of 
the proximal tubule. 
The tubule segments  forming  the loop of Henle 
generate the hypertonic environment in the medulla, 
necessary for concentrating the urine, and mediate the 
paracellular  reabsorption  of  Ca²+    and  Mg²+    under  the 
complex interactions between bone, parathyroid glands, 
intestine, and tubular segments, involving ﬁbroblast 
growth factor (FGF) 23, klotho, parathyroid hormone, and 
vitamin D.29,30 The kidney is also a main site of systemic 
oxygen sensing, regulating the oxygen supply to red blood 
cells and hence tissue oxygen supply by hypoxia-inducible 
erythropoietin production in peritubular ﬁbroblasts of the 
renal cortex.31 
Apart from  control of body homoeostasis, the kidney 
is  also  involved  in  immune   function.  Dendritic cells 
and macrophages, which form a network in the renal 
interstitium, contribute to innate and adaptive immunity 
and are increasingly recognised for their sentinel role 
against kidney injury and infection and their potential 
contribution  to  progression   of  kidney  disease.32      The 
renal  tubule  epithelial  cells  also  express  Toll-like 
receptors (TLRs), including TLR4, of the innate immune 
system and could be involved in triggering an innate 
immune  response to bacterial and viral infections or 
ischaemic stress.33 
 
 
Ultraﬁltrate containing plasma 
solutes and low-molecular-weight 
control of the Ca²+/Mg²+-sensing receptor.22  Specialised 
epithelial cells, located at the junction between the thick 
ascending   limb  of  the  loop  of  Henle  and  the  distal 
nephron (macula densa) sense the tubular NaCl concen- 
tration and interact with renin-containing granular cells 
in the aﬀerent arterioles to regulate the glomerular blood 
ﬂow through a mechanism  called tubuloglomerular 
feedback.23  The distal nephron, which includes the distal 
convoluted tubule, the connecting tubule, and the 
collecting ducts, is  responsive  to aldosterone and  vaso- 
pressin and regulates the ﬁnal urine composition and 
concentration.24  Several tubular transport processes  can 
be targeted by speciﬁc drugs, including diuretics, aqua- 
retics, calcimimetics, and the more recently developed 
inhibitors of glucose reabsorption.25 
Excretory, metabolic, and  endocrine  functions  of  the 
kidney  mediate  essential  interactions  with  several 
organs, sustaining an array of vital functions (ﬁgure 2), 
including regulation of body water and thirst, blood 
pressure,  ventilation, drug  metabolisation, potassium 
balance, erythropoiesis, calcium and phosphate metabol- 
ism, and acid-base homoeostasis. 
The regulation of NaCl excretion, which  is  crucial for 
extracellular ﬂuid volume and blood pressure  control, is 
inﬂuenced  by the renin-angiotensin-aldosterone system, 
the  atrial  natriuretic  peptide,  the  sympathetic  nervous 
proteins 
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system  and, to a lesser  extent, the antidiuretic hormone 
arginine  vasopressin.26    Renal excretion  of  potassium  is 
mainly dependent on the distal tubular ﬂow rate and the 
release of aldosterone and its action on the principal cells 
of  the  distal  nephron.  The  regulation  of  body  water 
content  (osmoregulation)  involves  the  action  of  vaso- 
pressin on aquaporin-mediated transport of water.27,28 The 
regulation of the phosphorus and calcium balance reﬂects 
 
 
 
 
 
 
 
Figure 1: Structure of the nephron 
Final urine with very low 
concentrations of proteins, 
no bicarbonate, and 
variable concentrations 
of electrolytes 
  
 
 
Kidney disease 
The present deﬁnition and staging of chronic kidney 
disease and acute kidney injury were proposed by 
independent guideline development workgroups.13,34 The 
criteria were based on, or were partly validated by, major 
research eﬀorts that have revolutionised the under- 
standing of outcomes of kidney disease. The foundation 
 for the deﬁnition and staging systems is the strong, 
graded, and consistent association of measures  of 
abnormalities in kidney structure and function with 
clinical prognosis, independent of age, sex, ethnic group, 
location, and comorbid conditions.35  The rationale for 
development of deﬁnitions and staging systems based on 
these  measures  is  the belief that uniform  terminology 
and explicit and objective criteria for assessment  enable 
Ventilation 
Acid-base homoeostasis 
Osmoregulation, thirst 
Ventilation Blood pressure 
Cardiac rhythm 
early identiﬁcation of kidney disease,  recognition of its 
health eﬀects, including regional and ethnic diﬀerences 
and----most importantly----the development of tailored 
interventions to improve outcomes. 
Chronic kidney disease and acute kidney injury can be 
detected straightforwardly by the non-nephrologist in 
clinical practice, and their prevalence and prognosis have 
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been rigorously studied as they relate to public health. 
However, measurements  for assessment  of kidney 
function and structure continue to evolve, the deﬁnitions 
of chronic kidney disease and acute kidney injury are not 
yet fully harmonised with each other, and evidence for 
improved outcomes because of the introduction of these 
deﬁnitions is not strong. 
Figure 3 shows  a conceptual model of the association 
of kidney disease, irrespective of duration, with adverse 
outcomes. Kidney disease is deﬁned as a heterogeneous 
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 group of disorders aﬀecting kidney structure and func- 
tion. Even  mild abnormalities in measures  of structure 
and function are associated with increased risk of kidney 
failure or development of complications in other organ 
systems, especially cardiovascular disease. The clinical 
presentation  and  course   of  the  disease   are   variable. 
Kidney disease can be deﬁned as acute or chronic, 
dependent on duration (≤3 months vs >3 months). Acute 
kidney injury  is deﬁned as  a subgroup  of acute kidney 
Figure 2: Eﬀect of kidney function on essential ho moeostatic processes 
FGF=ﬁbroblast growth factor. ANF=atrial natriuretic factor. 
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disease in which changes in kidney function occur within 
1 week. The association between acute kidney injury and 
chronic kidney disease  is  complex: acute kidney injury 
can lead to chronic kidney disease,  and chronic kidney 
disease increases the risk of acute kidney injury.36 
Table  1 summarises the deﬁnitions, stages, and burden 
of   chronic   kidney   disease   and   acute   kidney   injury. 
Both  disorders  are  deﬁned  by  objective  measures   of 
kidney damage (albuminuria, abnormalities in the urine 
sediment,  imaging,  or biopsy) and function (decreased 
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Kidney 
failure 
 
Death 
glomerular ﬁltration rate, increasing serum  creatinine 
concentrations, or decreased urine output), without 
reference to the cause of kidney disease. This feature is 
of particular importance because inclusion of the cause of 
kidney disease  would have precluded the application of 
Kidney disease 
 
 
Acute kidney injury 
Duration ≤3 months=acute 
Duration >3 months=chronic 
 
Change within 1 week 
the deﬁnition in epidemiological studies and in many 
clinical scenarios in which the cause was unknown or 
undocumented. Chronic kidney disease and acute kidney 
injury  are  categorised  into  stages  on  the  basis  of  the 
Figure 3: Factors associated  with  increased risk of kidney disease (blue),  stages of disease (green),  and 
co mplications (including death; purple) 
Horizontal arrows show transitions between stages (kidney outcomes). Solid arrows pointing from left to right 
show progression of kidney disease. Dashed arrowheads pointing from right to left show remission. Grey 
triangles show continuous nature of changes in glomerular ﬁltration rate and kidney damage. 
severity in abnormalities in these measures. Clinical 
practice   guidelines   for   both   disorders   emphasise    a 
stage-based approach to evaluation and management, 
complementing the traditional approaches emphasising 
  
 
 
 
 
 
Deﬁnition 
Chronic kidney disease Acute kidney injury 
Functional criteria GFR <60 mL/min per 1·73 m² for >3 months Increase in serum creatinine by 50% within 7 days; increase in serum creatinine by 
26·5 μmol/L (0·3 mg/dL) within 2 days; or oliguria 
Structural criteria Kidney damage for >3 months (albuminuria is the most common marker 
of kidney damage and is also associated with rapid progression) 
Staging GFR categories (mL/min per 1·73 m²) and related terms†: G1 ≥90 (normal 
or high); G2 60--89 (mildly decreased‡); G3a 45--59 (mildly to moderately 
decreased); G3b 30--44 (moderately to severely decreased); G4 15--29 
(severely decreased); G5 <15 (kidney failure) 
Albuminuria categories, approximate equivalent for AER (mg per day) and 
ACR (mg/g) and related terms: A1 <30 (normal to mildly increased); 
A2 30--300 (moderately increased‡); A3 >300 (severely increased‡) 
None 
 
Stages based on serum creatinine or urine output; stage 1: serum creatinine ≥1·5--1·9 times 
baseline, ≥26·5 μmol/L increase, or urine output <0·5 mL/kg per h for 6--12 h; stage 2: serum 
creatinine ≥2·0--2·9 times baseline or urine output <0·5 mL/kg per h for ≥12 h; stage 3: 
serum creatinine ≥3·0 times baseline, ≥353·6 μmol/L (≥4 mg/dL), renal replacement 
therapy, or (in patients <18 years) a decrease in estimated GFR to <35 mL/min per 1·73 m², 
urine output <0·3 mL/kg per h for ≥24 h, or anuria for ≥12 h 
Burden* 
Prevalence ~10% of adults (from 4% at 20---39 years to 47% at ≥70 years in the USA)6,8,37,38        Not applicable for a short-term illness (history of acute kidney injury of any severity present 
in 45% at chronic kidney disease stage ≥4)39 
Annual incidence ~1% in middle age; twice as frequent in black compared with white 
populations40--42 
Acute kidney injury requiring hospital admission in Alberta, Canada for patients without 
chronic kidney disease 0·1% (0·01% requiring dialysis); for patients with stage 3 disease 
0·5--7·1% (0·03--0·17%); for patients with stage 4 disease 7·0--11·7% (0·5--2·5%); and 34·8% 
for acute kidney injury of any severity in chronic kidney disease stage ≥439,43 
For patients already admitted to hospital, rates are ~10--20% for any acute kidney injury 
with 0·3% requiring dialysis (highest with sepsis, cancer and surgery) 
Lifetime cumulative 
incidence 
~50% for chronic kidney disease44  and ~2% in white and ~7% in black ·· 
populations for end-stage renal disease45,46 
 
GFR=glomerular ﬁltration rate. AER=albumin excretion rate. ACR=albumin-to-creatinine  ratio. *Varies by age and risk factor distribution.  †In the absence of evidence of kidney damage, GFR category G1 or G2 do not 
fulﬁl the criteria for chronic kidney disease. ‡Terms for categories G2 and A2 are relative to young adult levels; category A3 includes nephrotic syndrome (albumin excretion usually >2200 mg/day [ACR >2220 mg/g]). 
Table 1: Deﬁnitions, stages, and burden of chronic kidney disease and acute kidney injury 
 
 
cause of disease.4,13,34  The estimates of burden of disease 
are an approximation made on the basis of a synthesis of 
available data; substantial variation is  noted dependent 
on the number of risk factors assessed and availability of 
data in diﬀerent countries and regions. 
The juxtaposition of new deﬁnitions and staging 
systems (based mainly on laboratory measures)  and 
traditional notions (based primarily on causes of disease) 
has created substantial controversy within the specialty.47 
Such controversy has been inherently valuable in 
stimulating research, which has ultimately validated the 
new concepts and subsequently led to international 
collaborations and consensus.48 
Chronic kidney disease 
The impetus for the ﬁrst guidelines deﬁning chronic 
kidney disease in 2002 stemmed from the rising incidence 
and prevalence of chronic kidney failure, with associated 
high cost and poor outcomes, and concerns about late 
referral to nephrologists.4 The recommendations focused 
on estimation  of glomerular  ﬁltration rate from  serum 
creatinine  and  ascertainment  of markers  of kidney 
damage  (primarily albuminuria). Methodological issues 
about which measurements  to use were a key discussion 
point. Widespread variation in clinical laboratory pro- 
cedures for assaying and reporting of serum creatinine 
concentration drove international initiatives to standard- 
ise  assays  and develop more  accurate equations to 
estimate glomerular ﬁltration rate.49,50  Through inte- 
grated eﬀorts  of the clinical chemistry  and  nephrology 
communities, laboratories are now expected to use stan- 
dardised methods for creatinine assays and report 
estimated glomerular ﬁltration rate with validated esti- 
mating equations whenever possible.51,52 Subsequently, 
cystatin C was added as a variable to estimate glomerular 
ﬁltration rate and prognosis, leading to advances in 
detection and classiﬁcation of chronic kidney disease.53,54 
Standardisation and international consensus about urine 
albumin  measurements   is  an  active area  of  work.55    In 
2013, the global organisation Kidney Disease: Improving 
Global Outcomes (KDIGO)  published a chronic kidney 
disease   guideline  update34     that  adds   cause   of  kidney 
disease  and  albuminuria  stages  to the  staging  system, 
thus acknowledging the prognostic importance of albu- 
minuria concentrations.16,35,48 
Acute kidney injury 
KDIGO also developed an acute kidney injury guideline,13 
recognising  that  the  prognosis  of  acute  kidney  failure 
had not improved in decades, despite substantial improve- 
ments in intensive care and methods of dialysis, and that 
small declines in glomerular ﬁltration rate, which are not 
severe enough to be classiﬁed as acute kidney failure, are 
associated with adverse outcomes. The acute kidney injury 
guideline is based on earlier eﬀorts to deﬁne the 
disorder56,57 and concentrates on changes in serum 
creatinine or reduction in urine output as manifestations 
of direct injury to the kidney and acute impairment of 
function. Unlike chronic kidney disease, markers of 
damage are not included in the deﬁnition of acute kidney 
  
 
 
injury, but there is an intensive investigation of urinary 
biomarkers that precede the reduction in glomerular 
ﬁltration rate (eg, kidney injury molecule 1, neutrophil 
gelatinase-associated lipocalin, and  interleukin  18), and 
might allow early identiﬁcation and treatment.15,58 
Kidney as a cause and target organ of disease 
Diseases aﬀecting the kidney are usually categorised into 
primary and secondary diseases (table 2). However, with 
increased  understanding   of  the  underlying  causes   of 
disease,  this  classiﬁcation becomes  indistinct, because 
most  diseases  that mainly  manifest  in  the  kidney  are 
associated  with  extrarenal  pathogenesis  and  systemic 
manifestations.   In   view   of   its   notable   role   in   the 
circulation, the  kidney  is  frequently  a  target organ  of 
systemic   vascular,  haemodynamic,   metabolic,  and  in- 
ﬂammatory   disorders.  Involvement  of  the  kidney  in 
many    pathogenic   processes    originating   outside   the 
kidney    aggravates    disease    and    impairs    prognosis. 
Although many  kidney  diseases  are  rare  (and  are  the 
centre   of   specialised   nephrological   care),   increasing 
evidence  suggests  an  important  role  of  the  kidney  in 
highly  prevalent, complex  disorders,  including  obesity, 
diabetes, and hypertension. 
O besity, metabolic syndrom e, and diabetes 
Prevalence of obesity has increased substantially in the 
past  century.  In  the  USA,  obesity  (body-mass  index 
>30  kg/m²)  has  increased  in men  aged 60 years  from 
3.4% in 1890 to more than 30% in 2000.59  Obesity also 
presents  a  serious  health  threat  in  developing  coun- 
tries.60  The increase in obesity has been accompanied by 
notable  increases   in   hypertension,   diabetes,   cardio- 
vascular  disease,   and  chronic  kidney  disease.8,61     The 
association of chronic kidney disease with an increased 
frequency of obesity is partly because hypertension and 
diabetes are known causes of kidney disease and failure. 
Notably, however,  kidney  disease  begins  very  early  in 
people who go on to become obese. Thus, in individuals 
with the metabolic syndrome (a fat storage disorder that 
aﬀects  up  to 25%  of high-income populations, and  is 
characterised  by  truncal  obesity  in  combination  with 
any two of the following factors: increased  triglyceride 
concentrations, low  HDL cholesterol, increased  blood 
pressure, increased fasting plasma glucose levels, or 
previously diagnosed type 2 diabetes), the prevalence of 
chronic kidney disease increases with the number of 
traits.62  In turn, the presence  of chronic kidney disease 
in patients with metabolic syndrome increases their risk 
of development of cardiovascular disease. Why indiv- 
iduals  with  metabolic  syndrome  develop albuminuria 
and decreases  in glomerular ﬁltration rate before the 
development of signiﬁcant hypertension or diabetes is 
not known. One possibility is that underlying mech- 
anisms  might drive both kidney damage and metabolic 
syndrome, such as endothelial dysfunction and oxidative 
stress (which are common to both disorders). Diets high 
in added sugars might have a key role in development of 
metabolic  syndrome   and  kidney  disease,  particularly 
from the ingestion of fructose (present in sucrose and 
high-fructose corn syrup) that can lead to generation of 
uric acid.63  Mild kidney disease is induced in rats fed a 
high fructose diet.64 Low-grade systemic inﬂammation, 
which  is  also  present  in  these  disorders,  might  also 
result  in  changes  in  adipokines  and  other substances 
that can aﬀect glomerular capillary wall function.65 
Arterial hypertension 
The pathogenesis of hypertension shows that the kidney 
can have an important role in health and disease even 
when  renal  function,  deﬁned  by  glomerular  ﬁltration 
rate, is normal. Primary hypertension, deﬁned as a blood 
pressure of more than 140/90 mm Hg, was once present 
in only 5--10% of the adult population in the early 1900s, 
but has meanwhile  increased to a prevalence of 20--40% 
in most developed countries, and has been projected to 
aﬀect more than 1·5  billion people worldwide by 2025.66 
Most studies suggest that the underlying defect involved 
is a relative inability of the kidney to excrete salt, and this 
defect can be shown despite a normal or only slightly 
depressed    glomerular   ﬁltration   rate.67,68      A   character- 
istic   haemodynamic   ﬁnding   in   the   kidney   is   renal 
 
 
Exa mples of primary kidney diseases Exa mples of syste mic diseases aﬀecti ng the kidney 
 
Glomerular diseases Diﬀuse, focal or crescentic proliferative glomerulonephritis; 
focal and segmental glomerulosclerosis, membranous 
nephropathy, and minimal change disease 
Vascular diseases ANCA-associated renal limited vasculitis, and 
ﬁbromuscular dysplasia 
 
Obesity, metabolic syndrome and diabetes, systemic autoimmune 
diseases, systemic infections, drugs, complement diseases, and 
neoplasias and haemopoietic diseases 
Hypertension, atherosclerosis, ischaemia, cholesterol emboli, 
systemic vasculitis, thrombotic microangiopathy, and systemic 
sclerosis 
Tubulointerstitial diseases Urinary-tract infections, stones, and obstruction Systemic infections, sarcoidosis, drugs, urate, environmental 
toxins (eg, lead, aristolochic acid), and neoplasia (myeloma) 
Cystic and other congenital 
diseases 
Renal dysplasia, medullary cystic disease, and 
podocytopathies 
Autosomal-dominant polycystic kidney disease, Alport syndrome, 
and Fabry disease 
 
ANCA=antineutrophil cytoplasmic antibody. 
 
Table 2: Classiﬁcation of causes of chronic kidney disease based on presence or absence of syste mic disease and location within the kidney of 
pathological-anato mical ﬁndings 
  
 
 
 
M o nogenic disease Co m plex disease or trait 
 
Inheritance pattern and 
genetic risk 
Disease and genetic 
susceptibility prevalence 
 
Mendelian; mutations are necessary and often suﬃcient for disease 
manifestation, non-genetic risk factors have few associations 
Most monogenic diseases are individually rare* (eg, <1 in 
40 000 livebirths for recessive and <1 in 1000 for dominant 
diseases); ADPKD prevalence highest at ~1 per 1000 
 
Complex; many genetic factors with weak to moderate eﬀects (relative risk 1·05--1·5) combined 
with multiple non-genetic risk factors (relative risk 1·5--4·0) 
High for CKD (prevalence ~100 per 1000 adults); common risk allele frequencies (10--50%); 
much lower for speciﬁc chronic kidney disease subtypes such as IgA nephropathy or idiopathic 
membranous nephropathy 
Methods for discovery Linkage analysis, positional cloning, homozygosity mapping, 
sequencing (candidate genes or regions, whole exome, or genome) 
Association studies (candidate gene, genome-wide arrays) or sequencing, admixture mapping 
when a large genetic diﬀerence between populations is anticipated 
Examples ADPKD, Alport’s disease, and UAKD Population-based chronic kidney disease, estimated glomerular ﬁltration rate, and albuminuria, 
IgA nephropathy, and idiopathic membranous nephropathy 
Cause ADPKD†: mutations in PKD1 or PKD2 (currently 929 germline 
mutations in PKD1 and  167  in PKD2 classiﬁed as likely or deﬁnitely 
pathogenic; Alport’s disease: >500 pathogenic mutations in 
COL4A3-COL4A6; and UAKD: >50 pathogenic mutations in UMOD 
Multifactorial; genetic risk variants for chronic kidney disease or end-stage renal disease: APOL1, 
UMOD, PRKAG2, AFF3, RGMA/MCTP2, and WDR72; for estimated glomerular ﬁltration rate: 
ANXA9/LASS2, GCKR, ALMS1/NAT8, TFDP2, SHROOM3, DAB2, SLC34A1, VEGFA, PRKAG2, PIP5K1B, 
ATXN2/SH2B3, DACH1, UBE2Q2, UMOD, SLC7A9, SLC47A1, CASP9, CDK12, INO80, DDX1, MPPED2, 
MHC region,  and UNCX; for albuminuria: CUBN; for IgA nephropathy: HLA-DRB1/DQA1, PSMB8, 
HLA-DPA1/DPB2, CFHR3/R1, HORMAD2, TNFSF12/13,  DEFA9P-10P, HLA-DQB1/A2, MTMR3, 
HCG9, and SOX15/MPDU1; for idiopathic membranous nephropathy: HLA-DQA1 and PLA2R1 
 
Genes shown are the gene closest to the SNP with the lowest p value in an associated region, unless functional evidence points towards another nearby gene in the region. Only genome-wide signiﬁcant ﬁndings 
(p<5×10-⁸) are reported. CKD, estimated glomerular ﬁltration rate, and albuminuria loci are reported for ﬁndings from population-based studies, end-stage-renal disease ﬁndings are reported from case-control 
studies. ADPKD=autosomal-dominant polycystic kidney disease. UAKD=uromodulin-associated kidney disorders. *Aﬀecting fewer than ﬁve per 10 000 population. †For the ADPKD mutation database see 
http://pkdb.mayo.edu. 
Table 3: Monogenic and co mplex kidney diseases 
 
 
vasoconstriction, especially of the preglomerular arteri- 
olar vasculature. Genetic factors aﬀect the ability of the 
kidney to excrete salt69  and determine the risk of develop- 
ment of primary hypertension70  and hypertensive kidney 
disease.69,70  Intrauterine factors, known as fetal pro- 
gramming, are also important. In particular, intrauterine 
malnutrition can be associated with impaired fetal 
development, resulting in infants with a low birthweight 
who have a reduced number of nephrons in their kidney 
and are predisposed to the development of hypertension.71 
Hypertension  can  also  be  caused   by  subtle  acquired 
injury to the kidney, resulting in microvascular damage, 
peritubular capillary loss, and the inﬁltration of T  cells 
and macrophages.72  The inﬂammatory inﬁltrate enhances 
local oxidative stress  and intrarenal angiotensin activity, 
amplifying the renal vasoconstriction and impairing the 
excretion of salt. T  cells reacting to speciﬁc antigens in 
the kidney, possibly induced by local ischaemia, might 
contribute to the hypertensive response,73  thus suggesting 
an autoimmune component of primary hypertension. 
These mechanisms  might also explain how factors 
associated with the metabolic syndrome, such as endo- 
thelial dysfunction, sympathetic nervous overactivity, and 
hyperuricaemia can induce hypertension, thus providing 
an important link for the common coexistence of obesity 
and hypertension. 
Genetic predisposition to kidney disease 
Clustering of  kidney  disease  in  families  is  well  estab- 
lished,  but  underappreciated. From  the  1980s, linkage 
analysis and subsequently positional cloning emerged as 
a  technique  that allowed  for  the  detection of  disease- 
causing  mutations  in  one  gene  (termed  monogenic  or 
Mendelian  diseases).   In  2010,  more   than  110  genes 
underlying monogenic  diseases  with a renal phenotype 
had been described.74  The most prominent example is 
autosomal-dominant polycystic kidney disease  (table 3). 
Although this disease, which is the most frequent 
monogenic renal disorder usually manifests during 
adulthood, many  other rare monogenic renal diseases 
have an early and severe onset. With the advent of whole- 
exome and whole-genome sequencing, the number of 
identiﬁed single-gene defects causing renal disease in 
aﬀected families is expected to increase rapidly.75,76 Such 
studies will also allow researchers to investigate the 
combined eﬀect of rare mutations and common disease 
susceptibility variants, which might help explain some of 
the high phenotype heterogeneity reported for many 
monogenic kidney diseases. Overall monogenic diseases 
are the presumed  cause  of kidney failure in more than 
10% of patients undergoing dialysis, with autosomal- 
dominant polycystic kidney disease accounting for about 
7% of all failures.77 
Susceptibility to complex  multifactorial diseases  such 
as  chronic kidney disease  is  inﬂuenced  by  variation in 
many  genes  and  non-genetic components.  Since  2005, 
unbiased   genome-wide  mapping   approaches   such   as 
admixture    linkage   disequilibrium    and   genome-wide 
association studies  have emerged  as  methods  to search 
for    complex    kidney    disease    susceptibility    variants 
(table 3). These studies have identiﬁed genomic regions 
associated  with  intermediate  traits  such   as  estimated 
glomerular  ﬁltration rate,78,79  albuminuria,80    and  chronic 
kidney disease when applying the aforementioned deﬁni- 
tion of chronic kidney disease in the general population.79 
Moreover, genomic regions have been identiﬁed that are 
associated  with  more  speciﬁc  disease  entities  such  as 
non-diabetic  end-stage  renal   disease,   focal-segmental 
glomerulosclerosis,81--83 immunoglobulin A nephropathy,84 
and idiopathic membranous  nephropathy.85
 
  
 
 
As for other complex diseases, identiﬁed genetic risk 
variants usually  only confer  small  increases  in  disease 
risk, with identiﬁcation requiring large study popula- 
tions. Common risk variants in the MYH9/APOL1 region 
that increase the risk of kidney disease in black 
populations are an impressive exception because the 
associated relative risks are very large (ﬁvefold to 17-fold 
for focal-segmental glomerulosclerosis, threefold in case- 
control studies  of non-diabetic end-stage renal disease, 
and  29-fold for  HIV-associated nephropathy) and  the 
population attributable risk amounts to 70%.81,82,86 These 
risk alleles also contribute to the risk of diabetic kidney 
disease but the associated risk is smaller, suggesting that 
non-genetic factors  have  a  larger  role  than  do  genetic 
ones.87   The African American Study of Kidney Disease 
and Hypertension88  provided convincing evidence that 
progressive kidney disease that was labelled hypertensive 
nephrosclerosis  on clinical grounds  could be attributed 
to  risk  variants  in  the  APOL1 region,  explaining  why 
blood-pressure lowering often failed to halt disease 
progression in this population. The precise roles of 
MYH9/APOL1 in  predisposition  to  kidney  disease 
remain  to be identiﬁed, but apolipoprotein L1  confers 
protection against trypanosomiasis, which might have 
provided a survival advantage in Africans and thereby 
explains why this group is particularly at risk of focal- 
segmental  glomerulosclerosis  and non-diabetic chronic 
kidney disease.83 
The notion that a continuum  of genetic risk variants 
from  small  to large eﬀects results  in diﬀerent degrees 
of disease severity is compelling. Rare mutations in 
UMOD----which  codes  for uromodulin,  a  protein 
secreted in large amounts into the urine in the thick 
ascending limb of loop of Henle----cause monogenic 
kidney disease,89  whereas common UMOD variants 
increase chronic kidney disease susceptibility in the 
general population.90,91 Thus, disorders in uromodulin 
secretion are of widespread  pathophysiological rele- 
vance. Other rare inherited diseases  that have provided 
key insights into common  disorders of kidney function 
include monogenic disorders aﬀecting renal handling of 
NaCl, which  improved  our  understanding  of blood 
pressure regulation and mechanisms  of action of 
diuretics;92,93   inherited disorders  involving the proximal 
tubule such as renal Fanconi syndrome, which evidenced 
the role of receptor-mediated endocytosis in acquired 
proximal tubule dysfunction and renal disease pro- 
gression;94   and the discovery that several genes  causing 
cystic kidney diseases  code for proteins that are located 
in the primary cilium, which enlarged the scope of these 
disorders and provided essential information about their 
multisystemic nature.95 
Improved understanding of genetic causes of kidney 
disease has already started to inform treatment deci- 
sions. Identiﬁcation of a genetic cause  aﬀecting the 
glomerular ﬁltration barrier can help avoid ineﬀective 
exposure to steroid treatment in children with nephrotic 
syndrome.96   Genotyping for atypical haemolytic uraemic 
syndrome  can enable prediction of the risk for relapse 
after renal transplantation.97 The clinical relevance of 
genotyping in patients with kidney disease will probably 
increase rapidly in the near future. However, genetic 
insights   into  complex   kidney  diseases   have  not  yet 
proved useful  in terms  of prediction of chronic kidney 
disease in the general population.98 
Co m plications of kidney disease 
In general, all acute and chronic diseases have a worse 
prognosis in the presence of kidney disease. This 
association is of particular relevance for the various types 
of cardiovascular disease,9  including acute myocardial 
infarction,99  stroke,100 and heart failure.101 Chronic kidney 
disease also worsens the prognosis of patients with 
metabolic disease and diabetes, chronic pulmonary 
disease, pneumonia,102,103 and other acute infections. An 
increased incidence of cancer in patients with chronic 
kidney disease  has also been reported, but seems  to be 
linked to increased prevalence of liver cancer and 
urological cancer in these patients104 rather than a general 
increase in cancer risk. 
Reasons for the consistent association of kidney disease 
with poor outcomes are only partly understood. For 
patients whose kidney disease is a result of systemic 
disease processes leading to target organ damage at 
diﬀerent sites, the severity of kidney disease might show 
the severity of the systemic, damage-causing process. In 
addition, direct links exist between kidney function and 
the damage of extrarenal tissues. Acute kidney injury, for 
example, induces inﬂammation and aggravates the 
response to injury in the lung and other organs.105,106 The 
term cardiorenal syndrome  has been coined to describe 
the complex interaction between impaired cardiac func- 
tion and kidney disease, to which not only impaired renal 
salt and water handling but also enhanced renal 
sympathetic  activity contribute.107  Mechanisms  through 
which kidney disease accelerates atherosclerosis and 
enhances vascular calciﬁcations also warrant attention, 
with impaired  renal phosphate-handling presumably 
playing a dominant role.108  Not only is  vascular disease 
advanced in patients with chronic kidney disease, but 
several other characteristics of kidney disease might also 
be regarded as advanced ageing, possibly related to 
reduced renal expression  of the anti-ageing proteo- 
hormone klotho.29 
Presence of kidney disease also aﬀects management 
strategies and is associated with a reduced imple- 
mentation of best practice, presumably because of 
uncertainties about the risk-beneﬁt balance of diagnostic 
procedures and therapeutic interventions. Thus, restric- 
tions in the use of imaging  procedures that require the 
application of  radiocontrast agents  or  gadolinium  can 
lead to underdiagnosis in patients with kidney disease. 
Another potential source of impaired prognosis is error 
or  uncertainty  in  drug  dosing,  including  drug  toxicity 
  
 
 
and underdosing. Therapeutic nihilism  is especially 
obvious in the management of acute myocardial in- 
farction in patients with chronic kidney disease, who 
receive fewer  acute coronary interventions and reduced 
prescription of standard drugs, despite being at increased 
risk of adverse outcomes of myocardial ischaemia.109,110 
Implications for general practice 
In view of the importance of kidney function on body 
homoeostasis and the high prevalence of kidney disease, 
its  recognition  is  important  to all  providers  of  health 
care. Serum creatinine concentrations and urinary 
excretion of albumin related to creatinine in spot urine 
samples are straightforward and robust techniques to 
exclude or diagnose and stage chronic kidney disease.4,34 
Although the quantitative association between serum 
creatinine concentrations and glomerular ﬁltration rate 
is confounded by muscle mass, diﬀerent formulas have 
been developed to correct for this inﬂuence and to 
estimate glomerular  ﬁltration rate from one-oﬀ crea- 
tinine readings.34 Use of these formulas in clinical 
chemistry laboratories allows automatic reporting of 
estimated glomerular ﬁltration rate and thereby aids 
detection of kidney disease by the treating physician. 
Although screening  for chronic kidney disease in the 
general population has not been shown to be cost- 
eﬃcient, screening is recommended in high-risk groups, 
such as people with diabetes, hypertension, or a family 
burden of disease.111 
Treatment strategies for chronic kidney disease are 
diverse   and   depend   on   the   underlying   disease   and 
severity of impaired kidney function, complications, and 
comorbidities. However, blood-pressure control is a 
mainstay of secondary prevention for most patients. 
Inhibitors of the renin angiotensin system (angiotensin- 
converting-enzyme inhibitors or angiotensin receptor 
blockers) retard kidney disease progression beyond their 
blood-pressure-lowering eﬀects, presumably  because  of 
their inﬂuence on glomerular haemodynamics with a 
reduction in ﬁltration pressure.112   Attempts to further 
reduce kidney disease progression and cardiovascular 
complications through dual blockade of the renin-angio- 
tensin  system,  however,  have  failed.113,114 Irrespective of 
speciﬁc interventions, the recognition of patients with 
chronic kidney disease and acute kidney injury as 
individuals with high risk in all health-care settings is of 
utmost importance. 
Future challenges 
Despite the compelling evidence for strong associations 
of kidney disease with adverse outcomes and increasing 
insight into possible mechanisms,  the ultimate proof for 
a causal association between impaired kidney function 
and poor health will rely on proof of beneﬁt after 
improvements in kidney function. Unfortunately, thera- 
peutic  strategies  that would  enable  such  a  hypothesis 
to   be   addressed,   are   very   limited.   The  number   of 
randomised clinical trials in nephrology continues to lag 
behind most other medical specialties.115 In the context of 
clinical trials, kidney disease is usually an exclusion 
criterion and very rarely a therapeutic target. 
Because of the diverse mechanisms  that can aﬀect 
kidney function and the heterogeneity of natural courses 
of the disease, therapeutic interventions will probably not 
be eﬀective unless they are tailored to speciﬁc subgroups 
or stages of kidney disease. Thus, although a unifying 
perspective has proven crucial, the challenge of the future 
will be to subdivide the syndromes  of chronic kidney 
disease and acute kidney injury into distinct entities 
deﬁned by similar pathogenesis, disease states, and 
complications. New biomarkers  will be needed  that 
predict the risk of kidney disease in unaﬀected individuals 
and causes, pathomechanisms, and outcomes (renal and 
non-renal) in individuals with the disease. Integration of 
multilevel information, including genetics, pathological 
changes, biomarkers, clinical course, and drug response 
could eventually result in advanced versions of the present 
staging systems and form the basis for personalised 
therapies. The recent discovery of phospholipase  A2 as 
the main glomerular antigen causing membranous neph- 
ropathy, the most frequent cause of the nephrotic syn- 
drome in adults,116 the recognition of a speciﬁc genetic 
predisposition for this disease,85   the demonstration of 
increased antigen expression in glomeruli of aﬀected 
individuals,117  and the assessment  of phospholipase A2 
antibody titres as diagnostic techniques and indicators of 
disease activity provides an impressive  example for such 
an integrative approach.118 Apart from studies in single- 
disease entities, the establishment and prospective assess- 
ment of large cohorts of carefully characterised patients 
with chronic kidney disease will probably have an 
important role in unravelling distinct categories of kidney 
disease.119,120 If such approaches continue to be successful, 
the next major breakthrough in renal medicine will 
hopefully lead to eﬀective halting of kidney disease and its 
adverse outcomes through speciﬁc interventions, and 
ultimately regeneration of kidney function.121 
Contributors 
All authors discussed the overall concept, contributed to speciﬁc sections, 
and reviewed and approved the ﬁnal version. K-UE prepared the ﬁrst 
outline and integrated and edited contributions from all coauthors. 
Conﬂicts of interest 
We declare that we have no conﬂicts of interest. 
References 
1 Kerr M, Bray B, Medcalf J, O’Donoghue  DJ, Matthews B. 
Estimating the ﬁnancial cost of chronic kidney disease to the NHS 
in England. Nephrol Dial Transplant 2012; 27 (suppl 3): iii73--80. 
2 Vanholder R, Davenport A, Hannedouche T, et al, and the Dialysis 
Advisory Group of American Society of Nephrology. 
Reimbursement of dialysis: a comparison of seven countries. 
J Am Soc Nephrol 2012; 23: 1291--98. 
3 Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution 
of chronic kidney disease to the global burden of major 
noncommunicable diseases. Kidney Int 2011; 80: 1258--70. 
4 National Kidney Foundation. K/DOQI clinical practice guidelines for 
chronic kidney disease: evaluation, classiﬁcation, and stratiﬁcation. 
Am J Kidney Dis 2002; 39 (suppl 1): S1--266. 
  
 
 
5 Levey AS, Eckardt KU, Tsukamoto Y, et al. Deﬁnition and 
classiﬁcation of chronic kidney disease: a position statement from 
Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 
2005; 67: 2089--100. 
6 Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 
379: 165--80. 
7 James MT, Hemmelgarn BR, Tonelli M. Early recognition and 
prevention of chronic kidney disease. Lancet 2010; 375: 1296--309. 
8 Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney 
disease in the United States. JAMA 2007; 298: 2038--47. 
9 Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in 
chronic kidney disease. A clinical update from Kidney Disease: 
Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572--86. 
10     Sarnak MJ, Levey AS, Schoolwerth AC, et al, and the American 
Heart Association Councils on Kidney in Cardiovascular Disease, 
High Blood Pressure Research, Clinical Cardiology, and 
Epidemiology and Prevention. Kidney disease as a risk factor for 
development of cardiovascular disease: a statement from the 
American Heart Association Councils on Kidney in Cardiovascular 
Disease, High Blood Pressure Research, Clinical Cardiology, and 
Epidemiology and Prevention. Circulation 2003; 108: 2154--69. 
11       Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012; 
380: 756--66. 
12     Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after 
acute kidney injury: a systematic review and meta-analysis. 
Kidney Int 2012; 81: 442--48. 
13     KDIGO. KDIGO clinical practice guideline for acute kidney injury. 
Kidney Int Suppl 2012; 2: 1--138. 
14     Jha V, Garcia-Garcia  G, Iseki K, et al. Chronic kidney disease: global 
dimension and perspectives. Lancet 2013; published online May 31. 
http://dx.doi.org/10.1016/S0140-6736(13)60687-X. 
15     Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an 
increasing global concern. Lancet 2013; published online May 31. 
http://dx.doi.org/10.1016/S0140-6736(13)60647-9. 
16     Gansevoort  RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic 
kidney disease and cardiovascular risk: epidemiology, mechanisms, 
and prevention. Lancet 2013; published online May 31. http://dx.doi. 
org/10.1016/S0140-6736(13)60595-4. 
17      Luyckx  VA, Bertram JF, Brenner BM, et al. Eﬀect of fetal and child 
health on kidney development and long-term risk of hypertension 
and kidney disease. Lancet 2013; published online May 31. http:// 
dx.doi.org/10.1016/S0140-6736(13)60311-6. 
18     Remuzzi G, Benigni A, Finkelstein FO, et al. Kidney failure: aims 
for the next 10 years and barriers to success. Lancet 2013; published 
online May 31. http://dx.doi.org/10.1016/S0140-6736(13)60438-9. 
19     Haraldsson B, Nyström J, Deen WM. Properties of the glomerular 
barrier and mechanisms  of proteinuria. Physiol Rev 2008; 88: 451--87. 
20     Brown D, Bouley R, Păunescu TG, Breton S, Lu HA. New insights 
into the dynamic regulation of water and acid-base balance by renal 
epithelial cells. Am J Physiol Cell Physiol 2012; 302: C1421--33. 
21     Christensen EI, Verroust PJ, Nielsen R. Receptor-mediated 
endocytosis in renal proximal tubule. Pﬂugers Arch 2009; 
458: 1039--48. 
22     Ferrè S, Hoenderop JG, Bindels RJ. Sensing mechanisms  involved 
in Ca2+ and Mg2+ homeostasis. Kidney Int 2012; 82: 1157--66. 
23     Singh P, Thomson SC. Renal homeostasis and tubuloglomerular 
feedback. Curr Opin Nephrol Hypertens 2010; 19: 59--64. 
24     Reilly RF, Ellison DH. Mammalian distal tubule: physiology, 
pathophysiology, and molecular anatomy. Physiol Rev 2000; 
80: 277--313. 
25     Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliﬂozin: a novel 
sodium-glucose cotransporter type 2 inhibitor for the treatment of 
type 2 diabetes mellitus. Pharmacotherapy 2012; 32: 80--94. 
26     Stockand JD. Vasopressin regulation of renal sodium excretion. 
Kidney Int 2010; 78: 849--56. 
27     Schrier RW. Vasopressin and aquaporin 2 in clinical disorders of 
water homeostasis. Semin Nephrol 2008; 28: 289--96. 
28     Bourque CW. Central  mechanisms  of osmosensation and systemic 
osmoregulation. Nat Rev Neurosci 2008; 9: 519--31. 
29     Kuro-O M. Klotho in health and disease. 
Curr Opin Nephrol Hypertens 2012; 21: 362--68. 
30     Martin A, David V, Quarles LD. Regulation and function of the 
FGF23/klotho endocrine pathways. Physiol Rev 2012; 92: 131--55. 
31     Gleadle JM. Review article: how cells sense oxygen: lessons from 
and for the kidney. Nephrology (Carlton) 2009; 14: 86--93. 
32     Teteris SA, Engel DR, Kurts C. Homeostatic and pathogenic role of 
renal dendritic cells. Kidney Int 2011; 80: 139--45. 
33     Smith KD. Toll-like receptors in kidney disease. 
Curr Opin Nephrol Hypertens 2009; 18: 189--96. 
34     KDIGO. KDIGO clinical practice guideline for chronic kidney 
disease. Kidney Int Suppl 2013; 3: 1--150. 
35     Matsushita K, van der Velde M, Astor BC, et al, and the Chronic 
Kidney Disease Prognosis Consortium. Association of estimated 
glomerular ﬁltration rate and albuminuria with all-cause and 
cardiovascular mortality in general population cohorts: a collaborative 
meta-analysis.  Lancet 2010; 375: 2073--81. 
36     Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney 
disease: an integrated clinical syndrome. Kidney Int 2012; 82: 516--24. 
37     Matsushita K, Mahmoodi BK, Woodward  M, et al, and the Chronic 
Kidney Disease Prognosis Consortium. Comparison of risk 
prediction using the CKD-EPI equation and the MDRD study 
equation for estimated glomerular ﬁltration rate. JAMA 2012; 
307: 1941--51. 
38     Hallan SI, Matsushita K, Sang Y, et al, for the Chronic Kidney 
Disease Prognosis Consortium. Age and association of kidney 
measures with mortality and end-stage renal disease. JAMA 2012; 
308: 3349--60. 
39     Lafrance JP, Djurdjev O, Levin A. Incidence and outcomes of acute 
kidney injury in a referred chronic kidney disease cohort. 
Nephrol Dial Transplant 2010; 25: 2203--09. 
40     Bash LD, Coresh J, Köttgen A, et al. Deﬁning incident chronic kidney 
disease in the research setting: The ARIC Study. Am J Epidemiol 
2009; 170: 414--24. 
41     Fox CS, Larson  MG, Leip EP, Culleton  B, Wilson PW, Levy D. 
Predictors of new-onset kidney disease in a community-based 
population. JAMA 2004; 291: 844--50. 
42     Peralta CA, Katz R, DeBoer I, et al. Racial and ethnic diﬀerences in 
kidney function decline among persons without chronic kidney 
disease. J Am Soc Nephrol 2011; 22: 1327--34. 
43     James MT, Hemmelgarn BR, Wiebe N, et al, for the Alberta Kidney 
Disease Network. Glomerular ﬁltration rate, proteinuria, and the 
incidence and consequences of acute kidney injury: a cohort study. 
Lancet 2010; 376: 2096--103. 
44     Hoerger TJ, Wittenborn  JS, Segel JE, et al, and the Centers for 
Disease Control and Prevention CKD Initiative.  A health policy model of CKD: 1. Model  construction, assumptions, and validation of 
health consequences. Am J Kidney Dis 2010; 55: 452--62. 
45     Turin  TC, Tonelli M, Manns BJ, et al. Lifetime risk of ESRD. 
J Am Soc Nephrol 2012; 23: 1569--78. 
46     Kiberd BA, Clase CM. Cumulative risk for developing end-stage renal 
disease in the US population. J Am Soc Nephrol 2002; 13: 1635--44. 
47     Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Deﬁnition  and 
classiﬁcation of CKD: the debate should be about patient 
prognosis----a position statement from KDOQI and KDIGO. 
Am J Kidney Dis 2009; 53: 915--20. 
48     Levey AS, de Jong PE, Coresh J, et al. The deﬁnition, classiﬁcation, 
and prognosis of chronic kidney disease: a KDIGO Controversies 
Conference report. Kidney Int 2011; 80: 17--28. 
49     Levey AS, Coresh J, Greene T, et al, and the Chronic Kidney Disease 
Epidemiology Collaboration. Using standardized serum creatinine 
values in the modiﬁcation of diet in renal disease study equation for 
estimating glomerular ﬁltration rate. Ann Intern Med 2006; 
145: 247--54. 
50     Levey AS, Stevens LA, Schmid CH, et al, and the CKD-EPI (Chronic 
Kidney Disease Epidemiology Collaboration). A new equation to 
estimate glomerular ﬁltration rate. Ann Intern Med 2009; 150: 604--12. 
51     Myers GL, Miller  WG, Coresh J, et al, and the National Kidney 
Disease Education Program Laboratory Working Group. 
Recommendations for improving serum creatinine measurement: 
a report from the Laboratory Working Group of the National Kidney 
Disease Education Program. Clin Chem 2006; 52: 5--18. 
52     Miller WG. Estimating  glomerular ﬁltration rate. Clin Chem Lab Med 
2009; 47: 1017--19. 
53     Inker LA, Schmid CH, Tighiouart  H, et al, and the CKD-EPI 
Investigators. Estimating glomerular ﬁltration rate from serum 
creatinine and cystatin C. N Engl J Med 2012; 367: 20--29. 
  
 
 
 
54     Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney 
disease with creatinine, cystatin C, and urine albumin-to-creatinine 
ratio and association with progression to end-stage renal disease and 
mortality. JAMA 2011; 305: 1545--52. 
55     Miller WG, Bruns DE, Hortin GL, et al, and the National Kidney 
Disease Education Program-IFCC Working Group on 
Standardization of Albumin in Urine. Current issues in 
measurement  and reporting of urinary albumin excretion. 
Clin Chem 2009; 55: 24--38. 
56     Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, and the 
Acute Dialysis Quality Initiative workgroup. Acute renal failure---- 
deﬁnition, outcome measures, animal models, ﬂuid therapy and 
information technology needs: the Second International Consensus 
Conference of the Acute Dialysis Quality Initiative  (ADQI) Group. 
Crit Care 2004; 8: R204--12. 
57     Mehta RL, Kellum JA, Shah SV, et al, and the Acute Kidney Injury 
Network. Acute Kidney Injury Network: report of an initiative to 
improve outcomes in acute kidney injury. Crit Care 2007; 11: R31. 
58     Chawla LS, Kellum JA. Acute kidney injury in 2011: biomarkers are 
transforming our understanding of AKI. Nat Rev Nephrol 2012; 
8: 68--70. 
59     Helmchen LA, Henderson RM. Changes in the distribution of 
body mass index of white US men, 1890--2000. Ann Hum Biol 2004; 
31: 174--81. 
60     Dinsa GD, Goryakin Y, Fumagalli E, Suhrcke M. Obesity and 
socioeconomic status in developing countries: a systematic review. 
Obes Rev 2012; 13: 1067--79. 
61     United States Renal Data System. Atlas of end-stage renal disease 
in the United States. National Institute of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases. Annual 
Data Report, 2004. 
62     Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and 
chronic kidney disease in U.S. adults. Ann Intern Med 2004; 
140: 167--74. 
63     Johnson RJ, Sanchez-Lozada LG, Nakagawa T. The eﬀect of 
fructose on renal biology and disease. J Am Soc Nephrol 2010; 
21: 2036--39. 
64     Nakayama T, Kosugi T, Gersch M, et al. Dietary fructose causes 
tubulointerstitial injury in the normal rat kidney. 
Am J Physiol Renal Physiol 2010; 298: F712--20. 
65     Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates 
albuminuria and podocyte function in mice. J Clin Invest 2008; 
118: 1645--56. 
66     Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, 
He J. Global burden of hypertension: analysis of worldwide data. 
Lancet 2005; 365: 217--23. 
67     Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD 
Jr, Norman RA Jr. Arterial pressure regulation. Overriding 
dominance of the kidneys in long-term regulation and in 
hypertension. Am J Med 1972; 52: 584--94. 
68     Wadei HM, Textor SC. The role of the kidney in regulating arterial 
blood pressure. Nat Rev Nephrol 2012; 8: 602--09. 
69     Lifton RP. Genetic dissection of human blood pressure variation: 
common pathways from rare phenotypes. Harvey Lect 2004--2005; 
100: 71--101. 
70     Carmelli D, Robinette D, Fabsitz R. Concordance, discordance and 
prevalence of hypertension in World War II male veteran twins. 
J Hypertens 1994; 12: 323--28. 
71       Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number 
in patients with primary hypertension. N Engl J Med 2003; 
348: 101--08. 
72     Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular 
disease and interstitial inﬂammation in salt-sensitive hypertension. 
Hypertens Res 2010; 33: 975--80. 
73     Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the 
genesis of angiotensin II induced hypertension and vascular 
dysfunction. J Exp Med 2007; 204: 2449--60. 
74     Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375: 1287--95. 
75     Otto EA, Hurd TW, Airik R, et al. Candidate exome capture 
identiﬁes mutation of SDCCAG8 as the cause of a retinal-renal 
ciliopathy. Nat Genet 2010; 42: 840--50. 
76     Chaki M, Airik R, Ghosh AK, et al. Exome capture reveals ZNF423 
and CEP164 mutations, linking renal ciliopathies to DNA damage 
response signaling. Cell 2012; 150: 533--48. 
77     Devuyst  O, Antignac C, Bindels RJ, et al. The ERA-EDTA Working 
Group on inherited kidney disorders. Nephrol Dial Transplant 2012; 
27: 67--69. 
78     Chambers JC, Zhang W, Lord GM, et al. Genetic loci inﬂuencing 
kidney function and chronic kidney disease. Nat Genet 2010; 
42: 373--75. 
79     Köttgen A, Pattaro C, Böger CA, et al. New loci associated with 
kidney function and chronic kidney disease. Nat Genet 2010; 
42: 376--84. 
80     Böger CA, Chen MH, Tin A, et al, and the CKDGen Consortium. 
CUBN is a gene locus for albuminuria. J Am Soc Nephrol 2011; 
22: 555--70. 
81     Kao WH, Klag MJ, Meoni LA, et al, and the Family Investigation of 
Nephropathy and Diabetes Research Group. MYH9 is associated 
with nondiabetic end-stage renal disease in African Americans. 
Nat Genet 2008; 40: 1185--92. 
82     Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-eﬀect risk 
gene for focal segmental glomerulosclerosis. Nat Genet 2008; 
40: 1175--84. 
83     Genovese G, Friedman DJ, Ross MD, et al. Association of 
trypanolytic  ApoL1 variants with kidney disease in African 
Americans. Science 2010; 329: 841--45. 
84     Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association 
study identiﬁes susceptibility loci for IgA nephropathy. Nat Genet 
2011; 43: 321--27. 
85     Stanescu HC, Arcos-Burgos  M, Medlar A, et al. Risk HLA-DQA1 
and PLA(2)R1 alleles in idiopathic membranous  nephropathy. 
N Engl J Med 2011; 364: 616--26. 
86     Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in 
focal segmental glomerulosclerosis and HIV-associated 
nephropathy. J Am Soc Nephrol 2011; 22: 2129--37. 
87     Krop JS, Coresh J, Chambless LE, et al. A community-based study 
of explanatory factors for the excess risk for early renal function 
decline in blacks vs whites with diabetes: the Atherosclerosis Risk 
in Communities study. Arch Intern Med 1999; 159: 1777--83. 
88     Lipkowitz MS, Freedman BI, Langefeld CD, et al, and the SK 
Investigators. Apolipoprotein L1 gene variants associate with 
hypertension-attributed nephropathy and the rate of kidney 
function decline in African Americans. Kidney Int 2013; 83: 114--20. 
89     Hart TC, Gorry MC, Hart PS, et al. Mutations of the UMOD gene are 
responsible for medullary cystic kidney disease 2 and familial 
juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39: 882--92. 
90     Köttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated 
with indices of renal function and chronic kidney disease. Nat Genet 
2009; 41: 712--17. 
91     Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst  O. 
The rediscovery of uromodulin (Tamm-Horsfall protein): 
from tubulointerstitial nephropathy to chronic kidney disease. 
Kidney Int 2011; 80: 338--47. 
92     Ji W, Foo JN, O’Roak BJ, et al. Rare independent mutations in renal 
salt handling genes contribute to blood pressure variation. 
Nat Genet 2008; 40: 592--99. 
93     Devuyst  O. Salt wasting and blood pressure. Nat Genet 2008; 
40: 495--96. 
94     Devuyst  O, Thakker  RV. Dent’s disease. Orphanet J Rare Dis 2010; 
5: 28. 
95     Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med 
2011; 364: 1533--43. 
96     Santín S, Bullich G, Tazón-Vega  B, et al. Clinical utility of genetic 
testing in children and adults with steroid-resistant nephrotic 
syndrome. Clin J Am Soc Nephrol 2011; 6: 1139--48. 
97     Noris M, Remuzzi G. Genetics and genetic testing in hemolytic 
uremic syndrome/thrombotic thrombocytopenic purpura. Semin 
Nephrol 2010; 30: 395--408. 
98     O’Seaghdha CM, Yang Q, Wu H, Hwang SJ, Fox CS. Performance 
of a genetic risk score for CKD stage 3 in the general population. 
Am J Kidney Dis 2012; 59: 19--24. 
99     Go AS, Chertow GM, Fan D, McCulloch  CE, Hsu CY. Chronic 
kidney disease and the risks of death, cardiovascular events, and 
hospitalization. N Engl J Med 2004; 351: 1296--305. 
100  Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. 
Low glomerular ﬁltration rate and risk of stroke: meta-analysis. 
BMJ 2010; 341: c4249. 
  
 
 
 
101  Bagshaw SM, Cruz DN, Aspromonte N, et al. Epidemiology of 
cardio-renal syndromes: workgroup statements from the 7th ADQI 
Consensus Conference. NDT 2010; 25: 1406--16. 
102  Viasus D, Garcia-Vidal C, Cruzado JM, et al. Epidemiology, 
clinical features and outcomes of pneumonia in patients with 
chronic kidney disease. Nephrol Dial Transplant 2011; 
26: 2899--906. 
103  James MT, Quan H, Tonelli M, et al, and the Alberta Kidney 
Disease Network.  CKD and risk of hospitalization and death with 
pneumonia. Am J Kidney Dis 2009; 54: 24--32. 
104  Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. 
Cancer-speciﬁc mortality in chronic kidney disease: longitudinal 
follow-up of a large cohort. Clin J Am Soc Nephrol 2011; 6: 1121--28. 
105  Lie ML, White  LE, Santora RJ, Park JM, Rabb H, Hassoun HT. 
Lung  T lymphocyte traﬃcking and activation during ischemic 
acute kidney injury. J Immunol 2012; 189: 2843--51. 
106  Ahuja N, Andres-Hernando A, Altmann C, et al. Circulating IL-6 
mediates lung injury via CXCL1 production after acute kidney 
injury in mice. Am J Physiol Renal Physiol 2012; 303: F864--72. 
107  Ronco C, McCullough P, Anker SD, et al, and the Acute Dialysis 
Quality Initiative  (ADQI) consensus group. Cardio-renal 
syndromes: report from the consensus conference of the acute 
dialysis quality initiative. Eur Heart J 2010; 31: 703--11. 
108  Toussaint  ND, Pedagogos E, Tan SJ, et al. Phosphate in early 
chronic kidney disease: associations with clinical outcomes and a 
target to reduce cardiovascular risk. Nephrology (Carlton) 2012; 
17: 433--44. 
109  Charytan DM, Setoguchi S, Solomon DH, Avorn J, 
Winkelmayer WC. Clinical presentation of myocardial infarction 
contributes to lower use of coronary angiography in patients with 
chronic kidney disease. Kidney Int 2007; 71: 938--45. 
110  Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, 
Solomon DH, Avorn J. Kidney function and use of recommended 
medications after myocardial infarction in elderly patients. 
Clin J Am Soc Nephrol 2006; 1: 796--801. 
111    Levey  AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global 
public health problem: approaches and initiatives----a position 
statement from Kidney Disease Improving Global Outcomes. 
Kidney Int 2007; 72: 247--59. 
112  Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter  TH. 
Treatment of chronic kidney disease. Kidney Int 2012; 81: 351--62. 
113  Mann JF, Schmieder RE, McQueen  M, et al, and the ONTARGET 
investigators. Renal outcomes with telmisartan, ramipril, or both, in 
people at high vascular risk (the ONTARGET study): a multicentre, 
randomised, double-blind, controlled trial. Lancet 2008; 372: 547--53. 
114  Parving HH, Brenner BM, McMurray  JJ, et al, and the ALTITUDE 
Investigators. Cardiorenal end points in a trial of aliskiren for type 2 
diabetes. N Engl J Med 2012; 367: 2204--13. 
115  Palmer SC, Sciancalepore M, Strippoli  GF. Trial quality in nephrology: 
how are we measuring up? Am J Kidney Dis 2011; 58: 335--37. 
116  Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 
receptor as target antigen in idiopathic membranous nephropathy. 
N Engl J Med 2009; 361: 11--21. 
117     Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the 
M-type phospholipase A2 receptor in glomeruli correlates with serum 
receptor antibodies in primary membranous nephropathy. Kidney Int 
2012; 82: 797--804. 
118  Glassock  RJ. The pathogenesis of membranous nephropathy: 
evolution and revolution. Curr Opin Nephrol Hypertens 2012; 
21: 235--42. 
119  Lash JP, Go AS, Appel LJ, et al, and the Chronic Renal Insuﬃciency 
Cohort (CRIC) Study Group. Chronic Renal Insuﬃciency Cohort 
(CRIC) Study: baseline characteristics and associations with kidney 
function. Clin J Am Soc Nephrol 2009; 4: 1302--11. 
120  Eckardt KU, Bärthlein B, Baid-Agrawal S, et al. The German Chronic 
Kidney Disease (GCKD) study: design and methods. 
Nephrol Dial Transplant 2012; 27: 1454--60. 
121  Benigni A, Morigi M, Remuzzi G. Kidney regeneration. Lancet 
2010; 375: 1310--17. 
